Lenz Therapeutics Inc (LENZ)

$6.79 +0.07 (1.04%)
Market Cap 210.70M
Revenue (ttm) 19.09M
Net Income (ttm) -82.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -430.23%
Debt to Equity Ratio 0.00
Volume 374,800
Avg Vol 817,012
Day's Range N/A - N/A
Shares Out 31.35M
Stochastic %K 14%
Beta 0.58
Analysts Strong Sell
Price Target $30.17

Company Profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 925 7000
Address:
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States
TraderJoe65
TraderJoe65 Jun. 10 at 2:58 AM
$LENZ in what world does $BLCO not buy this outright
0 · Reply
Max_Regards
Max_Regards Jun. 9 at 2:06 PM
$LENZ I’m still here, holding till the bitter and or shiny beginnings.
1 · Reply
philipv777
philipv777 Jun. 8 at 5:05 PM
$LENZ markets unimpressed by the license deal? Only U.S numbers really matter I suppose …
4 · Reply
AlertsAndNews
AlertsAndNews Jun. 8 at 2:23 AM
$LENZ LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China "LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China. LENZ is also now eligible to receive additional payments in connection with the execution of the agreement between CORXEL and Everest."
0 · Reply
focafoca99
focafoca99 Jun. 7 at 11:53 PM
$LENZ secured an asset purchase agreement with Everest Medicines to commercialize VIZZ (LNZ100) in Greater China, unlocking up to $85
0 · Reply
Lunr2024
Lunr2024 Jun. 7 at 11:31 PM
$LENZ LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
0 · Reply
philipv777
philipv777 Jun. 5 at 1:24 PM
$LENZ The drug works. There is a market for it. Price is reasonable for the demographic they’re focusing on. The real question is, can a small company unlock the drug’s potential or do they need the marketing muscle of big pharma? Allergan did it with Restasis; created a market from scratch and banked a blockbuster. It was however covered by insurance. Can LENZ do it? With a lifestyle drug.
1 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 12:03 AM
$LENZ Share Price: $7.20 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.30 – $1.58 Potential Upside: 60% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TickrTalk0007
TickrTalk0007 Jun. 4 at 11:15 AM
$LENZ Presbyopia eye drop is a dead category
0 · Reply
jGoooo
jGoooo Jun. 2 at 3:02 PM
$LENZ mierda de compañia
1 · Reply
Latest News on LENZ
Lenz announces Everest Medicines acquired rights to develop VIZZ in China

2026-06-08T01:10:06.000Z - 2 days ago

Lenz announces Everest Medicines acquired rights to develop VIZZ in China

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

Jun 7, 2026, 7:30 PM EDT - 2 days ago

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZ Therapeutics to Participate in Upcoming Investor Conferences

May 26, 2026, 8:00 AM EDT - 14 days ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Lenz Therapeutics price target lowered to $20 from $26 at Citi

2026-05-13T10:43:53.000Z - 27 days ago

Lenz Therapeutics price target lowered to $20 from $26 at Citi

LENZ Therapeutics trading halted, volatility trading pause

2026-05-12T19:26:31.000Z - 4 weeks ago

LENZ Therapeutics trading halted, volatility trading pause

LENZ Therapeutics trading resumes

2026-05-12T19:21:07.000Z - 4 weeks ago

LENZ Therapeutics trading resumes

Lenz Therapeutics price target raised to $31 from $29 at BofA

2026-05-12T14:13:30.000Z - 4 weeks ago

Lenz Therapeutics price target raised to $31 from $29 at BofA

Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright

2026-05-12T10:17:53.000Z - 4 weeks ago

Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright

Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler

2026-05-12T09:16:13.000Z - 4 weeks ago

Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)

2026-05-11T23:50:20.000Z - 4 weeks ago

Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)

LENZ Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

LENZ Therapeutics Earnings Call Transcript: Q1 2026

LENZ Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

LENZ Therapeutics Earnings release: Q1 2026

LENZ Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:30 PM EDT - 4 weeks ago

LENZ Therapeutics Quarterly report: Q1 2026

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 11, 2026, 4:05 PM EDT - 4 weeks ago

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

May 4, 2026, 8:00 AM EDT - 5 weeks ago

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

LENZ Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

LENZ Therapeutics Proxy statement: Proxy filing

LENZ Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 6 weeks ago

LENZ Therapeutics Proxy statement: Proxy filing

Lenz Therapeutics price target lowered to $48 from $56 at H.C. Wainwright

2026-04-21T10:11:58.000Z - 7 weeks ago

Lenz Therapeutics price target lowered to $48 from $56 at H.C. Wainwright

Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%

2026-04-20T12:56:52.000Z - 7 weeks ago

Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

Apr 20, 2026, 8:00 AM EDT - 7 weeks ago

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

Lenz Therapeutics price target lowered to $26 from $52 at Citi

2026-03-26T10:31:04.000Z - 2 months ago

Lenz Therapeutics price target lowered to $26 from $52 at Citi

Lenz Therapeutics price target lowered to $29 from $35 at BofA

2026-03-25T11:22:03.000Z - 2 months ago

Lenz Therapeutics price target lowered to $29 from $35 at BofA

LENZ Therapeutics Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 2 months ago

LENZ Therapeutics Earnings Call Transcript: Q4 2025

LENZ Therapeutics Annual report: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 2 months ago

LENZ Therapeutics Annual report: Q4 2025

LENZ Therapeutics Earnings release: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 2 months ago

LENZ Therapeutics Earnings release: Q4 2025

Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)

2026-03-24T12:16:56.000Z - 2 months ago

Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 24, 2026, 8:00 AM EDT - 2 months ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

Mar 17, 2026, 8:00 AM EDT - 3 months ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

LENZ Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:00 AM EDT - 3 months ago

LENZ Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Lenz Therapeutics announces submission of MAA to EMA for VIZ

2026-03-10T12:38:41.000Z - 3 months ago

Lenz Therapeutics announces submission of MAA to EMA for VIZ

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

Mar 10, 2026, 8:00 AM EDT - 3 months ago

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

LENZ Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:50 AM EST - 3 months ago

LENZ Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

LENZ Therapeutics Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 3 months ago

LENZ Therapeutics Slides: Corporate presentation

LENZ Therapeutics to Present at Upcoming Investor Conferences

Feb 23, 2026, 8:00 AM EST - 3 months ago

LENZ Therapeutics to Present at Upcoming Investor Conferences

Citi says buy Lenz Therapeutics on ‘FAERS induced’ selloff

2026-02-19T20:55:33.000Z - 3 months ago

Citi says buy Lenz Therapeutics on ‘FAERS induced’ selloff

Lenz Therapeutics price target lowered to $35 from $52 at BofA

2026-02-04T14:31:51.000Z - 4 months ago

Lenz Therapeutics price target lowered to $35 from $52 at BofA

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Jan 14, 2026, 8:30 AM EST - 5 months ago

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Jan 7, 2026, 5:08 PM EST - 5 months ago

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Jan 5, 2026, 8:00 AM EST - 5 months ago

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

LENZ Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 4, 2025, 10:30 AM EST - 6 months ago

LENZ Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

LENZ Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 1:20 PM EST - 6 months ago

LENZ Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

LENZ Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 3:30 PM EST - 6 months ago

LENZ Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

Dec 1, 2025, 8:30 AM EST - 6 months ago

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

LENZ Therapeutics Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

LENZ Therapeutics Earnings Call Transcript: Q3 2025

LENZ Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

LENZ Therapeutics Earnings release: Q3 2025

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 5, 2025, 8:00 AM EST - 7 months ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 7 months ago

LENZ Therapeutics Slides: Corporate Presentation

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Oct 29, 2025, 8:00 AM EDT - 7 months ago

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 30, 2025, 8:05 AM EDT - 9 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 30, 2025, 8:00 AM EDT - 9 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

LENZ Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:00 AM EDT - 9 months ago

LENZ Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

LENZ Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:00 AM EDT - 9 months ago

LENZ Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

LENZ Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 1:45 PM EDT - 9 months ago

LENZ Therapeutics Transcript: Cantor Global Healthcare Conference 2025

LENZ Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 9:45 AM EDT - 9 months ago

LENZ Therapeutics Transcript: Citi's Biopharma Back to School Conference

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Aug 25, 2025, 8:00 AM EDT - 10 months ago

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

LENZ Therapeutics Transcript: Study Update

Aug 1, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Transcript: Study Update

LENZ Therapeutics Press release: Study Update

Aug 1, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Press release: Study Update

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

Jul 31, 2025, 4:05 PM EDT - 11 months ago

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Quarterly report: Q2 2025

LENZ Therapeutics Earnings release: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Earnings release: Q2 2025

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

Jul 28, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Jul 7, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

LENZ Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 4:00 PM EDT - 1 year ago

LENZ Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

LENZ Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 12:20 PM EDT - 1 year ago

LENZ Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 9, 2025, 9:03 AM EDT - 1 year ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

LENZ Therapeutics Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q1 2025

LENZ Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Quarterly report: Q1 2025

LENZ Therapeutics Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings release: Q1 2025

LENZ Therapeutics Slides: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Slides: Q1 2025

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 7, 2025, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

May 6, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

LENZ Therapeutics Transcript: Status Update

Apr 15, 2025, 2:00 PM EDT - 1 year ago

LENZ Therapeutics Transcript: Status Update

LENZ Therapeutics Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q4 2024

LENZ Therapeutics Annual report: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Annual report: Q4 2024

LENZ Therapeutics Earnings release: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings release: Q4 2024

LENZ Therapeutics Slides: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Slides: Q4 2024

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 19, 2025, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

LENZ Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:50 AM EST - 1 year ago

LENZ Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

LENZ Therapeutics to Host Commercial Day on April 15, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025

LENZ Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 3:30 PM EST - 1 year ago

LENZ Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

LENZ Therapeutics Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q3 2024

LENZ Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Quarterly report: Q3 2024

LENZ Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Earnings release: Q3 2024

LENZ Therapeutics Slides: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Slides: Q3 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Oct 27, 2024, 9:00 PM EDT - 1 year ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Oct 21, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS

LENZ Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 10:55 AM EDT - 1 year ago

LENZ Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

LENZ Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q2 2024

LENZ Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Quarterly report: Q2 2024

LENZ Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings release: Q2 2024

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Aug 12, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 7, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

LENZ Therapeutics Slides: KOL Event Presentation

Jun 18, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Slides: KOL Event Presentation

LENZ Therapeutics Slides: Corporate Presentation

Jun 13, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Slides: Corporate Presentation

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

Jun 10, 2024, 8:00 AM EDT - 2 years ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 2 years ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

LENZ Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

LENZ Therapeutics Earnings Call Transcript: Q1 2024

LENZ Therapeutics Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

LENZ Therapeutics Quarterly report: Q1 2024

LENZ Therapeutics Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

LENZ Therapeutics Earnings release: Q1 2024

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

May 1, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

Apr 3, 2024, 7:49 AM EDT - 2 years ago

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics Transcript: Study Result

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Transcript: Study Result

LENZ Therapeutics Press release: Study Result

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Press release: Study Result

LENZ Therapeutics Slides: Study Result

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Slides: Study Result

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Apr 2, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

Mar 21, 2024, 4:30 PM EDT - 2 years ago

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

TraderJoe65
TraderJoe65 Jun. 10 at 2:58 AM
$LENZ in what world does $BLCO not buy this outright
0 · Reply
Max_Regards
Max_Regards Jun. 9 at 2:06 PM
$LENZ I’m still here, holding till the bitter and or shiny beginnings.
1 · Reply
philipv777
philipv777 Jun. 8 at 5:05 PM
$LENZ markets unimpressed by the license deal? Only U.S numbers really matter I suppose …
4 · Reply
AlertsAndNews
AlertsAndNews Jun. 8 at 2:23 AM
$LENZ LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China "LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, as well as tiered mid single-digit to low double-digit royalties on net sales in Greater China. LENZ is also now eligible to receive additional payments in connection with the execution of the agreement between CORXEL and Everest."
0 · Reply
focafoca99
focafoca99 Jun. 7 at 11:53 PM
$LENZ secured an asset purchase agreement with Everest Medicines to commercialize VIZZ (LNZ100) in Greater China, unlocking up to $85
0 · Reply
Lunr2024
Lunr2024 Jun. 7 at 11:31 PM
$LENZ LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
0 · Reply
philipv777
philipv777 Jun. 5 at 1:24 PM
$LENZ The drug works. There is a market for it. Price is reasonable for the demographic they’re focusing on. The real question is, can a small company unlock the drug’s potential or do they need the marketing muscle of big pharma? Allergan did it with Restasis; created a market from scratch and banked a blockbuster. It was however covered by insurance. Can LENZ do it? With a lifestyle drug.
1 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 12:03 AM
$LENZ Share Price: $7.20 Contract Selected: Jan 15, 2027 $10 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.30 – $1.58 Potential Upside: 60% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TickrTalk0007
TickrTalk0007 Jun. 4 at 11:15 AM
$LENZ Presbyopia eye drop is a dead category
0 · Reply
jGoooo
jGoooo Jun. 2 at 3:02 PM
$LENZ mierda de compañia
1 · Reply
philipv777
philipv777 May. 29 at 8:58 PM
$LENZ good things happening in the background hopefully! Waiting patiently.
3 · Reply
philipv777
philipv777 May. 28 at 2:39 PM
$LENZ something cooking here?
6 · Reply
AlexSwiss77
AlexSwiss77 May. 27 at 10:57 PM
$LENZ I’m out for now from this May re enter at 5-6$
2 · Reply
Yasstocks
Yasstocks May. 27 at 1:05 PM
$LENZ I like it.
2 · Reply
Brabbit1000
Brabbit1000 May. 21 at 4:26 PM
$LENZ ahhh the classic dead cat bounce 😂 see everyone at $4!!
6 · Reply
ProfitMaker4
ProfitMaker4 May. 20 at 2:18 PM
$LENZ averaging down sub $7, heavy institutional ownership and great potential. LT Hold
2 · Reply
BioRich
BioRich May. 20 at 7:10 AM
$LENZ $PD $ELF $CRBP $NRSN Using this post for tracking over time. Cheers!
1 · Reply
Max_Regards
Max_Regards May. 15 at 2:37 PM
$LENZ going to wait until 1$ to double my position 😂
6 · Reply
aquira
aquira May. 15 at 2:09 PM
$LENZ danggg looks like there's no end in sight. My average is 8 ffs!!!
1 · Reply
Lunr2024
Lunr2024 May. 14 at 7:49 PM
$LENZ The market capitalization has fallen below cash value, yet there are still so many partners and potential milestone payments. I'm continuing to add to my position, and currently hold 16,800 shares. Also, I wonder if anyone has noticed that the company's chairman was formerly the global CEO of Alcon.
9 · Reply
AngryElf
AngryElf May. 14 at 6:38 PM
$LENZ You did not!
0 · Reply
US4nr
US4nr May. 14 at 6:16 PM
$LENZ First quarter sales could be mostly for building inventory at locations. Q1 sales look like a good (even small) signal as many of these are refills. It takes sometime to build a market, as long as they keep their burn reasonable. Launch is expensive but hopefully they'll tone it down and only double down to what is working. Personally I think it'll do OK but will never be a blockbuster drug. This indication will not be a billion dollar market anytime soon for any miotic eyedrop product unless they have no side effects whatsoever. We already have a supercheap treatment for presbyopia. It's called reading glasses. It should go back at $8:50-9 range soon and hope for Q2 sales to be over 3 million. I'm in at 7.6 with 5k shares for now.
1 · Reply